vs
Side-by-side financial comparison of Medpace Holdings, Inc. (MEDP) and MAXCYTE, INC. (MXCT). Click either name above to swap in a different company.
Medpace Holdings, Inc. is the larger business by last-quarter revenue ($708.5M vs $4.8M, roughly 148.0× MAXCYTE, INC.). Medpace Holdings, Inc. runs the higher net margin — 19.1% vs -200.5%, a 219.5% gap on every dollar of revenue. On growth, Medpace Holdings, Inc. posted the faster year-over-year revenue change (32.0% vs -20.9%). Medpace Holdings, Inc. produced more free cash flow last quarter ($188.1M vs $-2.9M). Over the past eight quarters, Medpace Holdings, Inc.'s revenue compounded faster (17.7% CAGR vs -7.4%).
Medpace Holdings, Inc. is a global clinical research organization (CRO) based in Cincinnati, Ohio, employing approximately 6,000 people. Operating under a full-service model, the company also offers global central laboratory, imaging core laboratory, and bioanalytical laboratory services, as well as a Phase I unit located on its headquarters and clinical research campus in Cincinnati, Ohio.
MaxCyte Inc. is a global biotechnology company focused on developing cell engineering platforms and enabling technologies for cell and gene therapy advancement. Its proprietary non-viral cell modification systems are widely used by pharmaceutical, biotech and life science research entities to develop immunotherapies, gene-edited treatments and next-generation biologic drugs from preclinical research through commercialization.
MEDP vs MXCT — Head-to-Head
Income Statement — Q4 2025 vs Q4 2025
| Metric | | |
|---|---|---|
| Revenue | $708.5M | $4.8M |
| Net Profit | $135.1M | $-9.6M |
| Gross Margin | — | — |
| Operating Margin | 21.6% | -234.5% |
| Net Margin | 19.1% | -200.5% |
| Revenue YoY | 32.0% | -20.9% |
| Net Profit YoY | 15.5% | 9.4% |
| EPS (diluted) | $4.65 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $708.5M | $4.8M | ||
| Q3 25 | $659.9M | $4.6M | ||
| Q2 25 | $603.3M | $5.8M | ||
| Q1 25 | $558.6M | $5.7M | ||
| Q4 24 | $536.6M | $6.1M | ||
| Q3 24 | $533.3M | $5.6M | ||
| Q2 24 | $528.1M | $5.0M | ||
| Q1 24 | $511.0M | $5.6M |
| Q4 25 | $135.1M | $-9.6M | ||
| Q3 25 | $111.1M | $-12.4M | ||
| Q2 25 | $90.3M | $-12.4M | ||
| Q1 25 | $114.6M | $-10.3M | ||
| Q4 24 | $117.0M | $-10.6M | ||
| Q3 24 | $96.4M | $-11.6M | ||
| Q2 24 | $88.4M | $-9.4M | ||
| Q1 24 | $102.6M | $-9.5M |
| Q4 25 | 21.6% | -234.5% | ||
| Q3 25 | 21.5% | -307.4% | ||
| Q2 25 | 20.9% | -244.3% | ||
| Q1 25 | 20.3% | -214.1% | ||
| Q4 24 | 23.4% | -213.1% | ||
| Q3 24 | 21.1% | -250.4% | ||
| Q2 24 | 19.9% | -241.0% | ||
| Q1 24 | 20.4% | -219.8% |
| Q4 25 | 19.1% | -200.5% | ||
| Q3 25 | 16.8% | -269.7% | ||
| Q2 25 | 15.0% | -212.2% | ||
| Q1 25 | 20.5% | -178.7% | ||
| Q4 24 | 21.8% | -175.0% | ||
| Q3 24 | 18.1% | -205.9% | ||
| Q2 24 | 16.7% | -188.8% | ||
| Q1 24 | 20.1% | -170.6% |
| Q4 25 | $4.65 | — | ||
| Q3 25 | $3.86 | $-0.12 | ||
| Q2 25 | $3.10 | $-0.12 | ||
| Q1 25 | $3.67 | — | ||
| Q4 24 | $3.67 | — | ||
| Q3 24 | $3.01 | $-0.11 | ||
| Q2 24 | $2.75 | $-0.09 | ||
| Q1 24 | $3.20 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $497.0M | $103.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $459.1M | $171.5M |
| Total Assets | $2.0B | $202.5M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $497.0M | $103.0M | ||
| Q3 25 | $285.4M | $105.7M | ||
| Q2 25 | $46.3M | $126.6M | ||
| Q1 25 | $441.4M | $138.3M | ||
| Q4 24 | $669.4M | $154.5M | ||
| Q3 24 | $656.9M | $153.8M | ||
| Q2 24 | $510.9M | $157.3M | ||
| Q1 24 | $407.0M | $157.5M |
| Q4 25 | $459.1M | $171.5M | ||
| Q3 25 | $293.6M | $180.3M | ||
| Q2 25 | $172.4M | $190.7M | ||
| Q1 25 | $593.6M | $199.4M | ||
| Q4 24 | $825.5M | $206.3M | ||
| Q3 24 | $881.4M | $213.3M | ||
| Q2 24 | $763.6M | $221.3M | ||
| Q1 24 | $671.5M | $226.4M |
| Q4 25 | $2.0B | $202.5M | ||
| Q3 25 | $1.8B | $213.5M | ||
| Q2 25 | $1.6B | $219.8M | ||
| Q1 25 | $1.9B | $230.0M | ||
| Q4 24 | $2.1B | $239.5M | ||
| Q3 24 | $2.1B | $248.6M | ||
| Q2 24 | $1.9B | $251.5M | ||
| Q1 24 | $1.8B | $257.9M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $192.7M | $-2.7M |
| Free Cash FlowOCF − Capex | $188.1M | $-2.9M |
| FCF MarginFCF / Revenue | 26.6% | -61.0% |
| Capex IntensityCapex / Revenue | 0.6% | 4.8% |
| Cash ConversionOCF / Net Profit | 1.43× | — |
| TTM Free Cash FlowTrailing 4 quarters | $681.9M | $-36.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $192.7M | $-2.7M | ||
| Q3 25 | $246.2M | $-7.5M | ||
| Q2 25 | $148.5M | $-9.9M | ||
| Q1 25 | $125.8M | $-14.4M | ||
| Q4 24 | $190.7M | $-7.8M | ||
| Q3 24 | $149.1M | $-4.4M | ||
| Q2 24 | $116.4M | $-4.8M | ||
| Q1 24 | $152.7M | $-10.6M |
| Q4 25 | $188.1M | $-2.9M | ||
| Q3 25 | $235.5M | $-7.8M | ||
| Q2 25 | $142.4M | $-10.4M | ||
| Q1 25 | $115.8M | $-15.1M | ||
| Q4 24 | $183.0M | $-8.0M | ||
| Q3 24 | $138.5M | $-4.8M | ||
| Q2 24 | $103.5M | $-5.1M | ||
| Q1 24 | $147.2M | $-11.4M |
| Q4 25 | 26.6% | -61.0% | ||
| Q3 25 | 35.7% | -168.5% | ||
| Q2 25 | 23.6% | -179.2% | ||
| Q1 25 | 20.7% | -262.3% | ||
| Q4 24 | 34.1% | -131.6% | ||
| Q3 24 | 26.0% | -85.5% | ||
| Q2 24 | 19.6% | -103.3% | ||
| Q1 24 | 28.8% | -203.6% |
| Q4 25 | 0.6% | 4.8% | ||
| Q3 25 | 1.6% | 6.5% | ||
| Q2 25 | 1.0% | 10.0% | ||
| Q1 25 | 1.8% | 11.4% | ||
| Q4 24 | 1.4% | 2.4% | ||
| Q3 24 | 2.0% | 7.2% | ||
| Q2 24 | 2.4% | 5.9% | ||
| Q1 24 | 1.1% | 14.4% |
| Q4 25 | 1.43× | — | ||
| Q3 25 | 2.22× | — | ||
| Q2 25 | 1.65× | — | ||
| Q1 25 | 1.10× | — | ||
| Q4 24 | 1.63× | — | ||
| Q3 24 | 1.55× | — | ||
| Q2 24 | 1.32× | — | ||
| Q1 24 | 1.49× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MEDP
| Metabolic | $249.8M | 35% |
| Oncology | $195.9M | 28% |
| Other | $88.3M | 12% |
| Central Nervous System | $73.2M | 10% |
| Cardiology | $63.0M | 9% |
| Antiviral And Anti Infective | $38.3M | 5% |
| Related Party | $10.3M | 1% |
MXCT
Segment breakdown not available.
